Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is N/A as of 2026-10-06T22:39:08.254Z.
Calculation as of: 2026-10-06T22:39:08.254Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
N/A
Veraxa Biotech Holding AG
Market Cap
$152.72M
EV/Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.58M
EV/Assets Ratio
8.23x
TTM Avg
6.94x
3Y Avg
19.02x
5Y Avg
19.02x
Market Cap
$153.79M
EV/Assets Ratio
1.68x
TTM Avg
1.43x
3Y Avg
1.27x
5Y Avg
0.95x
Market Cap
$151.01M
EV/Assets Ratio
6.42x
TTM Avg
7.17x
3Y Avg
5.63x
5Y Avg
4.08x
Market Cap
$149.36M
EV/Assets Ratio
0.85x
TTM Avg
1.09x
3Y Avg
1.12x
5Y Avg
1.12x
Market Cap
$148.73M
EV/Assets Ratio
21.26x
TTM Avg
0.90x
3Y Avg
0.55x
5Y Avg
0.45x
Market Cap
$148.64M
EV/Assets Ratio
0.74x
TTM Avg
0.86x
3Y Avg
0.75x
5Y Avg
0.77x
Market Cap
$148.27M
EV/Assets Ratio
0.25x
TTM Avg
2.06x
3Y Avg
3.13x
5Y Avg
3.62x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | 8.23x | 6.94x | 19.02x | 19.02x |
| Neuronetics, Inc. (STIM)vs › | $153.79M | 1.68x | 1.43x | 1.27x | 0.95x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | 6.42x | 7.17x | 5.63x | 4.08x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | 0.85x | 1.09x | 1.12x | 1.12x |
| Inogen, Inc. (INGN)vs › | $156.22M | 0.30x | 0.31x | 0.33x | 0.49x |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | 21.26x | 0.90x | 0.55x | 0.45x |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | 0.74x | 0.86x | 0.75x | 0.77x |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | 0.25x | 2.06x | 3.13x | 3.62x |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 1.02x | 0.99x | 0.60x | 0.57x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
